jxfzsy/iStock via Getty Images
Drug maker LianBio and hotel operator Atour each aims to raise about $350 million with separate New York listings
A year ago, the imminent IPO by Chinese company LianBio (LIAN) wouldn’t have drawn much
China-U.S. IPO Pipeline Creaks Back To Life With 2 New Listing Plans
Summary
- Two Chinese companies, drug maker LianBio and hotel operator Atour, are moving ahead with U.S. IPOs after a three-month pause on such listings.
- Neither company is using the controversial VIE structure, and neither comes from the sensitive internet sector.
- One place where we can expect big changes is in the “risk” section of Chinese companies going forward.
Bamboo Works provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies. Our founding team has more than a century of experience in Chinese and global media and capital markets, working for names including the Wall Street Journal, Reuters, Alibaba and JPMorgan. Drawing on that background, we provide in-depth coverage to drive informed decision-making for investors and others interested in this dynamic group of companies, many of them overlooked by mainstream media.